Conditions: Psoriasis
Keywords: chronic severe moderate treatment safety efficacy CP-690 550 Plaque psoriasis Psoriasis Vulgaris Psoriatic Arthritis tofacitinib Xeljanz
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 95
Healthy volunteers: no

Brief summary:
The main objective of this study is to evaluate the long term safety of CP-690,550 in patients being treated for moderate to severe plaque psoriasis and/or psoriatic arthritis. This study will also to compare the efficacy of two oral doses of CP-690,550 (5 mg BID and 10 mg BID) after 16 weeks of treatment.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: CP-690,550 intervention 2: CP-690, 550
Intervention descriptions: intervention 1: 10 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks. intervention 2: 5 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.

Protocol document: